Novo Nordisk的Amycretin口服减重药丸显示,在高剂量试验中体重下降13%,而安慰剂的减重率为1%。 Novo Nordisk's Amycretin oral weight loss pill demonstrated 13% weight loss in high-dose trials, compared to 1% with a placebo.

Novo Nordisk的口服减肥药Amycretin在早期试验中显示出令人乐观的结果,导致低剂量减肥10.4%,12周内较高剂量减肥13%以上。 Novo Nordisk's oral weight loss pill, Amycretin, has shown promising results in early trials, leading to a 10.4% weight loss at a low dose and over 13% at a higher dose over 12 weeks. 与安慰剂相比,损失率为1%。 This compares favorably to a 1% loss with a placebo. Amycretin针对GLP-1和Amylin荷尔蒙受体,可为肥胖症提供新的、更容易获得的治疗。 Targeting GLP-1 and amylin hormone receptors, Amycretin may offer a new, more accessible treatment for obesity. 目前正在进行较大规模的审判,预计今年晚些时候将取得结果。 Larger trials are underway, with results expected later this year.